---
figid: PMC6862668__ijms-20-05324-g001
figlink: /pmc/articles/PMC6862668/figure/ijms-20-05324-f001/
number: F1
caption: Signaling pathways and therapeutic targets. Normally, BMP9/TGFβ1 regulates
  angiogenesis through binding to ALK1/ENG to phosphorylate SMAD and increase PTEN
  activity, which in turn reduces PI3K signaling (blue lines and arrows). BMPs can
  also signal through MEK/ERK. In HHT (brown lines and arrows), mutation of ALK1 or
  ENG reduces pSMAD and PETN, resulting in increased PI3K activity or pERK level,
  causing AVM development. In sporadic AVM cases (red line and arrows), activating
  mutation in genes in the MAPK-ERK signaling pathway, such as KRAS, BRAF, and MAP2K1,
  increases the level of pERK, leading to AVM development or progression. The upregulation
  of PI3K may enhance AVM progression through exacerbation of angiogenesis in HHT.
  The genes in red can be tested as therapeutic targets.
pmcid: PMC6862668
papertitle: Recent Advances in Basic Research for Brain Arteriovenous Malformation.
reftext: Leandro Barbosa Do Prado, et al. Int J Mol Sci. 2019 Nov;20(21):5324.
pmc_ranked_result_index: '79504'
pathway_score: 0.9524494
filename: ijms-20-05324-g001.jpg
figtitle: Signaling pathways and therapeutic targets
year: '2019'
organisms:
- Homo sapiens
ndex: 09fa226a-dea1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6862668__ijms-20-05324-g001.html
  '@type': Dataset
  description: Signaling pathways and therapeutic targets. Normally, BMP9/TGFβ1 regulates
    angiogenesis through binding to ALK1/ENG to phosphorylate SMAD and increase PTEN
    activity, which in turn reduces PI3K signaling (blue lines and arrows). BMPs can
    also signal through MEK/ERK. In HHT (brown lines and arrows), mutation of ALK1
    or ENG reduces pSMAD and PETN, resulting in increased PI3K activity or pERK level,
    causing AVM development. In sporadic AVM cases (red line and arrows), activating
    mutation in genes in the MAPK-ERK signaling pathway, such as KRAS, BRAF, and MAP2K1,
    increases the level of pERK, leading to AVM development or progression. The upregulation
    of PI3K may enhance AVM progression through exacerbation of angiogenesis in HHT.
    The genes in red can be tested as therapeutic targets.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - AKT1
  - AKT2
  - BMP10
  - GDF2
  - RAF1
  - ENG
  - KRAS
  - MAP2K1
  - MAP2K2
  - EIF2AK3
  - PIK3R6
  - PIK3R5
  - PIK3R4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PTEN
  - RORC
  - VEGFA
  - KDR
  - AVM
  - Cancer
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: BMP10
  symbol: BMP10
  source: hgnc_symbol
  hgnc_symbol: BMP10
  entrez: '27302'
- word: BMP9
  symbol: BMP-9
  source: hgnc_alias_symbol
  hgnc_symbol: GDF2
  entrez: '2658'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: ENG
  symbol: ENG
  source: hgnc_symbol
  hgnc_symbol: ENG
  entrez: '2022'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: +PERK
  symbol: PERK
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK3
  entrez: '9451'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: +PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: TOR
  symbol: TOR
  source: hgnc_alias_symbol
  hgnc_symbol: RORC
  entrez: '6097'
- word: VEGF-A
  symbol: VEGF-A
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
chemicals:
- word: AVM
  source: MESH
  identifier: C051113
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC6862668__F1
redirect_from: /figures/PMC6862668__F1
figtype: Figure
---
